PROQR THERAPEUTICS EO-04 (F:0PQ) — Stock Price
PROQR THERAPEUTICS EO-04 (F:0PQ) is currently trading at €1.58 EUR, down 1.25% today. Over the past 52 weeks, shares have ranged between €1.14 and €2.56. This page tracks PROQR THERAPEUTICS EO-04's live share price on the F exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see 0PQ market cap.
PROQR THERAPEUTICS EO-04 (0PQ) Stock Price Chart — Daily History & Trading Volume
The chart below tracks PROQR THERAPEUTICS EO-04's daily closing share price and trading volume on the F exchange over the past year, giving a clear view of recent price momentum and liquidity.
PROQR THERAPEUTICS EO-04 Income Statement — Revenue, Profit & Earnings by Year
PROQR THERAPEUTICS EO-04's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | €15.91 Million | €18.91 Million | €6.51 Million | €3.59 Million | €1.33 Million |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Research & Development | €44.73 Million | €36.36 Million | €25.15 Million | €50.87 Million | €42.22 Million |
| SG&A | €15.06 Million | €13.66 Million | €16.24 Million | €18.65 Million | €17.37 Million |
| Total Operating Expenses | €59.35 Million | €49.38 Million | €41.30 Million | €68.75 Million | €58.55 Million |
| Operating Income | €-43.45 Million | €-30.47 Million | €-34.79 Million | €-65.16 Million | €-57.21 Million |
| EBITDA | — | — | — | — | — |
| EBIT | — | — | — | — | — |
| Interest Expense | €929.00K | €1.08 Million | €1.20 Million | €5.13 Million | €3.40 Million |
| Income Before Tax | €-42.16 Million | €-27.96 Million | €-27.81 Million | €-64.11 Million | €-60.68 Million |
| Income Tax Expense | — | — | — | — | — |
| Net Income | €-42.18 Million | €-27.76 Million | €-28.12 Million | €-64.42 Million | €-60.74 Million |
PROQR THERAPEUTICS EO-04 Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes PROQR THERAPEUTICS EO-04's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | €112.76 Million | €167.96 Million | €137.88 Million | €171.32 Million | €209.58 Million |
| Total Current Assets | €100.13 Million | €153.84 Million | €120.99 Million | €154.46 Million | €191.48 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | — | — | — |
| Net Receivables | €3.36 Million | €0.00 | — | — | — |
| Inventory | — | — | — | — | — |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | — | — | — | — | — |
| Total Liabilities | €63.38 Million | €79.40 Million | €96.49 Million | €104.64 Million | €96.35 Million |
| Total Current Liabilities | €32.44 Million | €38.90 Million | €34.20 Million | €20.99 Million | €27.60 Million |
| Long-term Debt | — | — | €4.29 Million | €4.27 Million | €39.32 Million |
| Net Debt | — | — | — | — | — |
| Total Stockholder Equity | €49.37 Million | €88.56 Million | €41.39 Million | €67.06 Million | €113.83 Million |
| Retained Earnings | €-467.51 Million | €-427.16 Million | €-400.85 Million | €-379.11 Million | €-317.77 Million |
PROQR THERAPEUTICS EO-04 Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how PROQR THERAPEUTICS EO-04 generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | €-52.79 Million | €-36.39 Million | €21.55 Million | €-68.51 Million | €-26.01 Million |
| Capital Expenditures | €1.02 Million | €1.42 Million | €1.37 Million | €708.00K | €484.00K |
| Free Cash Flow | €-53.81 Million | €-37.81 Million | €20.18 Million | €-69.22 Million | €-26.50 Million |
| Investing Cash Flow | — | — | — | — | — |
| Financing Cash Flow | €-1.84 Million | €70.28 Million | €-2.27 Million | €-30.89 Million | €136.83 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | €4.01 Million | €2.54 Million | €3.11 Million | €2.87 Million | €6.22 Million |
| Depreciation | €2.70 Million | €2.76 Million | €2.51 Million | €2.52 Million | €2.33 Million |
| Change in Cash | €-55.65 Million | €29.81 Million | €23.55 Million | €-100.10 Million | €110.39 Million |
PROQR THERAPEUTICS EO-04 Earnings History — EPS Actual vs. Analyst Estimates
Track PROQR THERAPEUTICS EO-04's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| May 08, 2026 | — | -0.18 | — |
| Mar 12, 2026 | — | -0.18 | — |
| Nov 06, 2025 | -0.10 | -0.17 | +41.18% |
| Aug 07, 2025 | -0.12 | -0.17 | +29.41% |
| May 08, 2025 | -0.10 | -0.09 | -7.76% |
| Mar 13, 2025 | -0.09 | -0.09 | +4.86% |
| Nov 07, 2024 | -0.10 | -0.11 | +5.66% |
| Aug 08, 2024 | -0.03 | -0.12 | +75.00% |